GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.20
Ask: 5.30
Change: 0.05 (0.96%)
Spread: 0.10 (1.923%)
Open: 5.15
High: 5.25
Low: 5.10
Prev. Close: 5.20
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

Wed, 13th Dec 2023 09:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Impellam Group PLC, up 26% at 819.12 pence, 12-month range 580.00p-950.00p. Shares in the staffing firm rise, though back off from new 52-week high, after it says it has agreed to a GBP483.2 million takeover offer from Heather Global PLC, a bidding vehicle for HeadFirst Global BV. The HeadFirst offer values each Impellam share at 1,084.4 pence in total. This represents a 67% premium over the stock's 650.00p close in London on Tuesday. The offer is supported by Impellam's majority owner Michael Ashcroft, a UK businessman who was formerly deputy chair of the UK Conservative Party.

----------

Allergy Therapeutics PLC, up 9.5% at 2.13p, 12-month range 0.37p-5.64p. The biotechnology firm, focused on allergy vaccines, updates on G306 Phase III trial of Grass MATA MPL, its short-course subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. It notes "highly significant secondary efficacy endpoints with an acceptable safety and tolerability profile observed for Grass MATA MPL." Chief Executive Manuel Llobet says: "We are very pleased that the primary and secondary endpoints from this trial strongly align, and all data analysed demonstrate the beneficial effect of our Grass MATA MPL product. These data, alongside the results from our earlier G309 field study, provide a strong, significant and consistent data package for our discussions with relevant health authorities."

----------

AIM - LOSERS

----------

Future Metals NL, down 12% at 1.30p, 12-month range 1.13p-6.40p. The West Perth-based exploration company focused on the Panton platinum group metals project in Western Australia says its shares have been suspended on the Australian Securities Exchange in Sydney pending the release of an announcement in relation to a "potential capital raising". The company's shares continue to trade as normal on AIM in London.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
23 Jul 2015 08:38

Allergy Therapeutics Expects Revenue Growth Despite Euro Weakness

Read more
6 Jul 2015 07:43

Allergy Therapeutics dust mite study yields positive results

Pharmaceutical group Allergy Therapeutics has announced positive results from a clinical study for the treatment of house dust mite allergy. Results of the observational one-year follow-up study of Acarovac Plus showed that there were no adverse effects to the tolerability of the product, while ther

Read more
6 Jul 2015 07:36

Allergy Therapeutics Gets Good Results From Acarovac Plus Study

Read more
2 Jul 2015 08:07

Allergy Therapeutics To Host Allergy Conference In Amsterdam

Read more
25 Jun 2015 07:40

Allergy Therapeutics Resumes Allergy Treatment US Clinical Programme

Read more
5 Jun 2015 11:14

Allergy Therapeutics buys Alerpharma for 3.8m euros

Specialty pharmaceutical company Allergy Therapeutics said on Friday that it has agreed to buy Alerpharma SA for an initial consideration of €3.8m. Alerpharma wholly owns the Spanish-based allergy immunotherapy company Instituto de Immunologia y Alergia (Inmunal),which is a spin-out of biopharmaceut

Read more
5 Jun 2015 10:14

Allergy Therapeutics Acquires Alerpharma For Up To EUR5.8 Million

Read more
10 Mar 2015 12:42

UK MIDDAY BRIEFING: The Man From The Pru To Leave On High Note

Read more
10 Mar 2015 12:05

UK WINNERS & LOSERS: Oil Stocks, Gold Miners Hit By Price Weakness

Read more
10 Mar 2015 10:30

Allergy Therapeutics Raises GBP20.8 Million In Share Placing (ALLISS)

Read more
2 Mar 2015 09:46

Allergy Therapeutics Ups Profit, Revenue, Market Share In First Half

Read more
12 Jan 2015 08:52

Allergy Therapeutics To Post 4% Rise In First-Half Revenue

Read more
30 Sep 2014 10:35

Allergy Therapeutics Extends Convertible Loan With Abbott Labs' CFR

Read more
22 Sep 2014 09:06

Allergy Therapeutics Profit Up, Optimistic For Future On US Prospects

Read more
22 Sep 2014 05:20

UK Earnings, Trading Statements Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.